IN2014MN02652A - - Google Patents
Info
- Publication number
- IN2014MN02652A IN2014MN02652A IN2652MUN2014A IN2014MN02652A IN 2014MN02652 A IN2014MN02652 A IN 2014MN02652A IN 2652MUN2014 A IN2652MUN2014 A IN 2652MUN2014A IN 2014MN02652 A IN2014MN02652 A IN 2014MN02652A
- Authority
- IN
- India
- Prior art keywords
- compounds
- infections
- esters
- useful
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657550P | 2012-06-08 | 2012-06-08 | |
| PCT/US2013/044826 WO2013185103A1 (fr) | 2012-06-08 | 2013-06-07 | Inhibiteurs macrocycliques des virus flaviviridae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02652A true IN2014MN02652A (fr) | 2015-08-21 |
Family
ID=48692655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2652MUN2014 IN2014MN02652A (fr) | 2012-06-08 | 2013-06-07 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9145441B2 (fr) |
| EP (1) | EP2861604B1 (fr) |
| JP (1) | JP6209601B2 (fr) |
| KR (1) | KR20150040265A (fr) |
| CN (1) | CN104703991B (fr) |
| AU (1) | AU2013270672B2 (fr) |
| BR (1) | BR112014030630A2 (fr) |
| CA (1) | CA2875692A1 (fr) |
| EA (1) | EA026235B1 (fr) |
| ES (1) | ES2624223T3 (fr) |
| HK (2) | HK1209730A1 (fr) |
| IL (1) | IL236005A0 (fr) |
| IN (1) | IN2014MN02652A (fr) |
| MX (1) | MX2014014766A (fr) |
| NZ (2) | NZ703040A (fr) |
| PL (1) | PL2861604T3 (fr) |
| PT (1) | PT2861604T (fr) |
| SG (1) | SG11201408047XA (fr) |
| SI (1) | SI2861604T1 (fr) |
| WO (1) | WO2013185103A1 (fr) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| SG11201408045UA (en) | 2012-06-08 | 2015-01-29 | Gilead Sciences Inc | MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES |
| ES2624223T3 (es) | 2012-06-08 | 2017-07-13 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de los virus flaviviridae |
| US20190022116A1 (en) | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
| CU20170115A7 (es) | 2015-03-04 | 2018-03-13 | Gilead Sciences Inc | Compuestos moduladores de receptor de tipo toll |
| WO2017007892A1 (fr) * | 2015-07-07 | 2017-01-12 | Nch Corporation | Système et procédé de traitement de l'eau avec un biocide biologique |
| CA2995004A1 (fr) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Modulateurs deuteres du recepteur toll |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
| EP3454856A4 (fr) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
| SG11201809893WA (en) | 2016-05-27 | 2018-12-28 | Gilead Sciences Inc | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| CN109923106B (zh) | 2016-09-02 | 2022-09-13 | 吉利德科学公司 | toll样受体调节剂化合物 |
| SG11201903042VA (en) | 2016-10-14 | 2019-05-30 | Precision Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2018137959A1 (fr) | 2017-01-25 | 2018-08-02 | Basf Se | Procédé de préparation d'amides benzyliques |
| TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| EP3601267A1 (fr) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-méthyl-quinazolines |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| AU2018319538B9 (en) | 2017-08-22 | 2021-05-27 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CA3082191C (fr) | 2017-12-07 | 2021-09-21 | Emory University | N4-hydroxycytidine et derives et leurs utilisations anti-virales |
| ES2927860T3 (es) | 2017-12-13 | 2022-11-11 | Lupin Ltd | Compuestos heterocíclicos bicíclicos sustituidos como inhibidores de PRMT5 |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| EP3774883A1 (fr) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチド |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781565A1 (fr) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-méthyl-aza-quinazolines |
| CA3093130C (fr) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Inhibiteurs pd-1/pd-l1 |
| WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
| AU2019297428C1 (en) | 2018-07-06 | 2023-03-23 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| AU2019301811B2 (en) | 2018-07-13 | 2022-05-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| WO2020086556A1 (fr) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Inhibiteurs de pd-1/pd-l1 |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| CN112969505B (zh) | 2018-10-31 | 2023-11-14 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CA3140708A1 (fr) | 2019-06-18 | 2020-12-24 | Helen Horton | Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de pyridopyrimidine |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| WO2021011891A1 (fr) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Formulations à action prolongée de ténofovir alafénamide |
| EP4017476A1 (fr) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3160142A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
| US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
| WO2021198981A1 (fr) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Composés antiviraux et leurs utilisations |
| EP4192474A1 (fr) | 2020-08-07 | 2023-06-14 | Gilead Sciences, Inc. | Promédicaments d'analogues nucléotidiques de phosphonamide et leur utilisation pharmaceutique |
| CN116457358A (zh) | 2020-09-15 | 2023-07-18 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
| EP4214204A1 (fr) | 2020-09-18 | 2023-07-26 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines en tant qu'inhibiteurs de sos1 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (fr) | 2021-04-14 | 2022-10-19 | Bayer AG | Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1 |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US20230060354A1 (en) | 2021-06-23 | 2023-03-02 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
| US20240109915A1 (en) | 2022-07-29 | 2024-04-04 | Pfizer Inc. | Novel acc inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| CA2612344A1 (fr) | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrogues d'antagonistes de recepteur d'adenosine a2b |
| ATE524183T1 (de) * | 2005-06-17 | 2011-09-15 | Novartis Ag | Verwendung von sanglifehrin bei der hcv-therapie |
| EP2011786A1 (fr) | 2007-07-05 | 2009-01-07 | Laboratorios del Dr. Esteve S.A. | Dérivés d'indanamine, leur préparation et utilisation en tant que médicaments |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009088256A2 (fr) | 2008-01-09 | 2009-07-16 | Konkuk University Industrial Cooperation Corp | Vaccins à base de baculovirus |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CA2745565C (fr) * | 2008-12-23 | 2017-03-07 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Procedes et intermediaires pour preparer un inhibiteur macrocyclique de protease du vhc |
| WO2011063233A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryles comme modulateurs de la bêta-secrétase et procédés d'utilisation |
| EA021196B1 (ru) * | 2010-01-15 | 2015-04-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
| WO2011090935A1 (fr) | 2010-01-19 | 2011-07-28 | Merck Sharp & Dohme Corp. | Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor |
| WO2011098808A1 (fr) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Composés à base de sangliféhrine |
| GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| EP2618665A4 (fr) * | 2010-09-21 | 2014-08-20 | Merck Sharp & Dohme | Inhibiteurs de protéase ns3 du vhc |
| AR084217A1 (es) | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| SG11201408093PA (en) | 2012-06-08 | 2015-01-29 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
| ES2624223T3 (es) | 2012-06-08 | 2017-07-13 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de los virus flaviviridae |
| SG11201408045UA (en) | 2012-06-08 | 2015-01-29 | Gilead Sciences Inc | MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
-
2013
- 2013-06-07 ES ES13731203.9T patent/ES2624223T3/es active Active
- 2013-06-07 PL PL13731203T patent/PL2861604T3/pl unknown
- 2013-06-07 NZ NZ703040A patent/NZ703040A/en not_active IP Right Cessation
- 2013-06-07 SG SG11201408047XA patent/SG11201408047XA/en unknown
- 2013-06-07 IN IN2652MUN2014 patent/IN2014MN02652A/en unknown
- 2013-06-07 MX MX2014014766A patent/MX2014014766A/es unknown
- 2013-06-07 EA EA201492209A patent/EA026235B1/ru not_active IP Right Cessation
- 2013-06-07 PT PT137312039T patent/PT2861604T/pt unknown
- 2013-06-07 EP EP13731203.9A patent/EP2861604B1/fr not_active Not-in-force
- 2013-06-07 KR KR1020157000171A patent/KR20150040265A/ko not_active Application Discontinuation
- 2013-06-07 CN CN201380039194.XA patent/CN104703991B/zh not_active Expired - Fee Related
- 2013-06-07 CA CA2875692A patent/CA2875692A1/fr not_active Abandoned
- 2013-06-07 SI SI201330574A patent/SI2861604T1/sl unknown
- 2013-06-07 JP JP2015516260A patent/JP6209601B2/ja not_active Expired - Fee Related
- 2013-06-07 BR BR112014030630A patent/BR112014030630A2/pt not_active Application Discontinuation
- 2013-06-07 WO PCT/US2013/044826 patent/WO2013185103A1/fr active Application Filing
- 2013-06-07 US US13/913,259 patent/US9145441B2/en not_active Ceased
- 2013-06-07 AU AU2013270672A patent/AU2013270672B2/en not_active Ceased
- 2013-06-07 NZ NZ724503A patent/NZ724503A/en not_active IP Right Cessation
-
2014
- 2014-11-30 IL IL236005A patent/IL236005A0/en unknown
-
2015
- 2015-08-07 US US14/821,458 patent/US9512175B2/en not_active Expired - Fee Related
- 2015-10-22 HK HK15110379.3A patent/HK1209730A1/xx not_active IP Right Cessation
- 2015-12-04 HK HK15111999.1A patent/HK1211285A1/xx unknown
-
2017
- 2017-09-25 US US15/715,080 patent/USRE47334E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9512175B2 (en) | 2016-12-06 |
| NZ703040A (en) | 2016-11-25 |
| SI2861604T1 (sl) | 2017-05-31 |
| MX2014014766A (es) | 2015-05-11 |
| JP6209601B2 (ja) | 2017-10-04 |
| US20150344521A1 (en) | 2015-12-03 |
| JP2015518904A (ja) | 2015-07-06 |
| ES2624223T3 (es) | 2017-07-13 |
| EP2861604A1 (fr) | 2015-04-22 |
| US20140030221A1 (en) | 2014-01-30 |
| HK1209730A1 (en) | 2016-04-08 |
| AU2013270672B2 (en) | 2017-10-19 |
| BR112014030630A2 (pt) | 2017-06-27 |
| SG11201408047XA (en) | 2015-01-29 |
| CN104703991B (zh) | 2018-03-23 |
| HK1211285A1 (en) | 2016-05-20 |
| KR20150040265A (ko) | 2015-04-14 |
| PT2861604T (pt) | 2017-05-05 |
| US9145441B2 (en) | 2015-09-29 |
| EA201492209A1 (ru) | 2015-05-29 |
| WO2013185103A1 (fr) | 2013-12-12 |
| IL236005A0 (en) | 2015-02-01 |
| PL2861604T3 (pl) | 2017-08-31 |
| CN104703991A (zh) | 2015-06-10 |
| AU2013270672A1 (en) | 2015-01-22 |
| CA2875692A1 (fr) | 2013-12-12 |
| NZ724503A (en) | 2017-12-22 |
| EP2861604B1 (fr) | 2017-03-01 |
| EA026235B1 (ru) | 2017-03-31 |
| USRE47334E1 (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02652A (fr) | ||
| IN2014MN02657A (fr) | ||
| IN2014MN02658A (fr) | ||
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| HK1166788A1 (fr) | ||
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
| MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
| IN2012DN01855A (fr) | ||
| IN2015DN01156A (fr) | ||
| WO2014028600A3 (fr) | Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci | |
| IN2015DN01119A (fr) | ||
| MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
| IN2011CH03893A (fr) |